Perspectives on the impact of painful diabetic peripheral neuropathy in a multicultural population

Abstract

BackgroundSince few studies have characterized painful diabetic peripheral neuropathy (pDPN) symptoms in multicultural populations, this study fielded a survey to better understand pDPN and its impact in African-American, Caucasian, and Hispanic populations.MethodsKelton fielded a survey by phone or Internet, in English or Spanish, among adults with pDPN symptoms in the United States between August and October 2015; African-Americans and Hispanics were oversampled to achieve at least 500 subjects for each group. Patients were required to have been diagnosed with pDPN or score ≥ 3 on ID Pain validated screening tool. The survey elicited information on pDPN symptoms and interactions with healthcare providers (HCPs), and included the Brief Pain Inventory and pain-specific Work Productivity and Assessment Questionnaire (WPAI:SHP).ResultsRespondents included 823 Caucasians, 525 African-Americans, and 537 Hispanics; approximately half of African-Americans and Hispanics were <40 years of age, vs 12% of Caucasians. Pain was less likely to be rated moderate or severe by African-Americans (65%) and Hispanics (49%) relative to Caucasians (87%; p < 0.05). African-Americans and Hispanics were less likely than Caucasians to report experiencing specific pDPN sensory symptoms. Significantly fewer African-Americans and Hispanics reported receiving a pDPN diagnosis relative to Caucasians (p < 0.05), and higher proportions of African-Americans and Hispanics reported difficulty communicating with their HCP (p < 0.05). WPAI:SHP activity impairment was lower in Hispanics (43%) relative to African-Americans (53%) and Caucasian (56%; p < 0.05).ConclusionsMulticultural patients reported differences in pDPN symptoms and pain relative to Caucasians, and fewer received a pDPN diagnosis. While further evaluation is needed to understand these differences, these data suggest a need to broaden pDPN educational initiatives to improve patient-HCP dialogue and encourage discussion of pDPN symptoms and their impact in a multicultural setting.Electronic supplementary materialThe online version of this article (10.1186/s40842-017-0051-2) contains supplementary material, which is available to authorized users.

Prevalence and risk factors for painful diabetic neuropathy in secondary healthcare in Qatar

“…Other studies have also reported that a large proportion of patients with PDPN were not diagnosed, 61.5% in Germany 7 and 12.5% in the UK 8 . Major hurdles limiting the diagnosis of PDPN are that patients with painful symptoms do not attribute them to diabetes and fail to report them to their physician 8,9 , and of course screening is not currently advocated for PDPN, only for those at high risk of foot ulceration 31 . Given that we have identified age, duration of diabetes and the presence of impaired vibration perception as major determinants for PDPN 1,5,6,10 , one could advocate screening for PDPN in at least diabetes patients who are older, have a longer duration of diabetes and impaired vibration perception.…”

“…Despite having a serious impact on the patient's quality of life, PDPN is underdiagnosed and undertreated 7,8 . Patients with painful symptoms are often unaware that the pain is related to diabetes, and do not report it to their clinician 8,9 . Screening patients at high risk for PDPN should allow timely identification and treatment.…”

Long‐term safety and efficacy of mirogabalin in Asian patients with diabetic peripheral neuropathic pain

“…Diabetic peripheral neuropathy is present in up to half of all patients with long‐standing diabetes mellitus, and up to one‐third will develop diabetic peripheral neuropathic pain (DPNP) DPNP is a major cause of morbidity, often worsening quality of life, as well as being associated with a significant economic burden. DPNP often results in sleep disturbance, and the constant tiredness from disturbed sleep and painful symptoms during the day leads to limitations in daily activities and work productivity. DPNP symptoms are also frequently associated with depression and anxiety.…”

Experience in using nucleotides for the management Of patients with diabetic polyneuropatie

“…В условиях роста заболеваемости ожидается увеличе-ние распространенности ранних и поздних диабетиче-ских осложнений с поражением сердечно-сосудистой, нервной системы, органа зрения [7][8][9]. Нередко первым поводом для обращения пациента к врачам различных специальностей являются не классические проявления гипергликемии, а симптомы осложнений СД: полинейро-патия, ретинопатия, нефропатия, хроническая сердечная недостаточность, язвенные дефекты стоп и др.…”

“…Далее, по мере вовлечения в патологический процесс НЕВРОЛОГИЯ крупных миелинизированных волокон, появляются боле-вые ощущения: от покалывания, жжения до выраженного болевого синдрома [7,16]. Стойкая невропатическая боль доставляет существенные страдания пациентам, является одной из сложных проблем в лечении больных СД.…”